NEA invests $4.3M in Cartiva's joint replacement work

Cartiva, developer of a cartilage replacement implant for osteoarthritis patients, has pulled in $4.3 million in new financing. The Georgia company plans to use the money to finish clinical testing of its signature product and support a planned FDA PMA submission when the time comes. The implant is made of a cartilage-like polymer, and meant to be a more effective, less invasive alternative to a fusion procedure. Global VC firm New Enterprise Associates led the round, and NEA partner Justin Klein has now joined Cartiva's board of directors. Cartiva spun off of Carticept Medical in December 2011. Release

Suggested Articles

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.

The FDA has announced a series of actions aimed at limiting the use of power morcellators in gynecologic surgeries.

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.